Hyperkalemia-related treatment changes linked to death in acute HF
November 21, 2019
It’s not the potassium, but the subsequent dosage reduction, that may boost mortality after hospitalization for acute heart failure.
First reversal agent for apixaban and rivaroxaban gets fast-track approval
May 4, 2018
Andexanet alfa approval puts factor Xa inhibitors in the same ballpark as dabigatran, reversible with idarucizumab.
Post-ACS death lowered in ODYSSEY Outcomes
March 10, 2018
ORLANDO – Mortality and major adverse cardiovascular events were cut 15%, but that’s not all.